0001683168-23-007145.txt : 20231013 0001683168-23-007145.hdr.sgml : 20231013 20231013143801 ACCESSION NUMBER: 0001683168-23-007145 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231009 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231013 DATE AS OF CHANGE: 20231013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANNAPHARMARX, INC. CENTRAL INDEX KEY: 0001081938 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274635140 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27055 FILM NUMBER: 231324829 BUSINESS ADDRESS: STREET 1: SUITE 3600 STREET 2: 888 3RD STREET SW CITY: CALGARY STATE: A0 ZIP: T2P 5C5 BUSINESS PHONE: 949-652-6838 MAIL ADDRESS: STREET 1: SUITE 3600 STREET 2: 888 3RD STREET SW CITY: CALGARY STATE: A0 ZIP: T2P 5C5 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN DRAGON HOLDING CO. DATE OF NAME CHANGE: 20110125 FORMER COMPANY: FORMER CONFORMED NAME: CCVG, INC. DATE OF NAME CHANGE: 20101117 FORMER COMPANY: FORMER CONFORMED NAME: CONCORD VENTURES, INC. DATE OF NAME CHANGE: 20071003 8-K 1 cannapharmarx_8k.htm CURRENT REPORT
0001081938 false 0001081938 2023-10-09 2023-10-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 9, 2023

 

CannaPharmaRX, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 333-251016 27-4635140

(State or other jurisdiction of incorporation)

(Commission File Number) (IRS Employer ID No.)

 

Suite 3600, 888-3rd Street SW

Calgary, Alberta, Canada T2P 5C5

(Address of principal executive offices, including zip code)

 

(949) 652-6838

(Registrant’s Telephone Number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share CPMD OTC Markets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

   

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Chief Financial Officer

 

Effective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc. (the “Company,” “we,” “us”) effective June 1, 2023. There was no disagreement between us and Mr. Cassels on any matter related to our operations, policies or practices that led to Mr. Cassels’s replacement as CFO. Mr. Cassels has been an important and integral part of our changes and growth since our inception. We wish Mr. Cassels all the best in his future endeavors and is grateful for his service to us.

 

Effective October 13, 2023, our Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer. Mr. Foeste has consented to such appointment. Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLP and has significant executive, director, finance, and public company compliance experience across a number of industry sectors including cannabis and nutraceuticals.  Prior to Invictus, Mr. Foeste was in senior finance and accounting roles at TSX, TSXV, and NYSE listed issuers, and earned his CPA at Deloitte and a boutique tax advisory firm.

 

On July 25, 2023, we engaged Mr. Foeste and Invictus to provide us backup Chief Financial Officer and accounting services. Both us and Mr. Foeste agreed that if both parties agreed, Mr. Foeste would eventually succeed Mr. Cassels as our Chief Financial Officer. Under this engagement Invictus professionals, under the direction of Mr. Foeste, would provide us certain accounting and financial services. Under this engagement, we would be billed hourly based upon the service and individual providing the service. The hourly rate would range from $65 to $400 per hour. Further, if he were named as our Chief Financial Officer, Mr. Foeste would, and by his appointment is, entitled to annual bonuses and/or stock options similar to those issued to other officers or as recommended by the Board of Director’s and other reimbursement of certain expenses.

 

The description of the engagement above does not purport to be complete and is qualified in its entirety by reference to the Invictus engagement letter, a copy of which is filed as Exhibit 9.01 to this Current Report on Form 8-K and is incorporated herein by reference.

 

There are no other arrangements or understandings between Mr. Foeste and any other persons pursuant to which Mr. Foeste was appointed as the Company’s Chief Financial Officer. There are no family relationships between Mr. Foeste and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number

Description
9.01 Engagement Letter between CannaPharmaRX, Inc. and Invictus Accounting Group LLP (Oliver Foeste) dated July 25, 2023
104 Cover Page Interactive Data File formatted in inline XBRL

 

 

 

 

 

 

 2 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  CANNAPHARMARX, INC.
   
October 13, 2023 By: /s/ Dean Medwid
    Dean Medwid
CEO

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

EX-9.01 2 cannapharmarx_ex0901.htm ENGAGEMENT LETTER

Exhibit 9.1

 

 

 

July 25, 2023

 

Mr. Dean Medwid
Chief Executive Officer
CannaPharmaRX Inc.
3600 888 3rd Street SW
Calgary, AB T2P 5C5

 

Re:      CFO and Accounting Advisory Services - 2023

 

Dear Mr. Medwid:

 

Introduction

 

The purpose of this engagement letter (the "Agreement"), together with the Standard Terms and Conditions attached hereto, is to confirm our understanding of the terms of our engagement to provide the services set out below (the "Services") to CannaPharmaRX Inc. (the "Company", or "you"). Unless otherwise defined hereinafter, capitalized terms used herein shall have the meaning ascribed to them in the attached Standard Terms and Conditions.

 

Scope of Our Services

 

You have engaged Invictus Accounting Group LLP ("Invictus" or the "Firm") to provide Chief Financial Officer ("CFO") services, financial reporting services, accounting/bookkeeping services, and other accounting and tax accounting advisory services, as follows:

 

A.CFO Services — Invictus will provide part-time CFO services which include assisting with financial projections and budgets, assisting with aspects of the Company's strategic plan, assisting with M&A activities, attending select shareholder, Director, and management/executive meetings, overseeing the Company's accounting team, overseeing quarterly and annual financial reporting, enacting improvements to accounting processes and controls (as applicable), and overseeing payroll and tax compliance.

 

  o Oliver Foeste, Managing Partner at Invictus, will become named CFO of the Company at a time the parties agree is acceptable for both of them.

 

B.Financial Reporting Services — Invictus will provide part-time quarterly and annual financial reporting services including drafting of the consolidation, financial statements and related working papers, assisting with preparation of the MD&A, preparation of technical accounting analysis/memos, assistance with deferred income tax provision, and auditor liaison, as applicable.

 

 

 

1400 — 1199 West Hastings Street, Vancouver BC, V6E 3T5

 

   

 

 

C.Bookkeeping Services — Invictus will provide part-time parent-level bookkeeping/accounting services including recording expenses, monthly accounting close and reconciliations, preparing GST filings, et al. Bookkeeping services may expand to include subsidiary accounting, as applicable.

 

D.Ad hoc Accounting. and Tax Advisory Services / Projects — As specifically requested by the Company, Invictus will assist the Company with ad hoc accounting and tax advisory projects, which are reasonably outside of the scope of the services noted above. In the event Invictus is asked to prepare corporate tax return(s), Invictus shall provide a separate engagement letter for such services.

 

For certainty, any Ad hoc Accounting and Tax Advisory Services / Projects must be specifically requested/pre-approved by the Company.

 

Non-Assurance

 

We will be providing services as consultants, and not as the Company's auditor, and as such the procedures we will be performing under this engagement will not constitute an examination, review, or audit in accordance with generally accepted auditing standards or attestation standards.

 

Key Assumptions

 

Our work can be completed timely, and in the most cost-efficient manner, provided that your staff is available to answer our questions and provide requested documents during the course of work.

 

The Company's Responsibilities

 

The Company shall provide Invictus with all information relevant to the Services and any reasonable assistance as may be required to properly perform the Services. The Company represents and warrants to Invictus that all such information will be accurate and complete in all material respects. The overall definition and scope of the work to be performed, and its adequacy in addressing the Company's needs, is the Company's responsibility. The Company shall perform all management functions and make all management decisions in connection with the Services, and shall assign competent individuals to oversee the Services. The Company is also responsible for the implementation of actions identified in the course of this engagement as well as the results achieved from using any output from the Services and Deliverables (as defined below).

 

Project Outputs / Deliverables

 

Project outputs, as applicable, will be provided in a MS Office (Word, Excel, PowerPoint, Outlook), PDF, or other format as applicable (the "Deliverables") and as requested by the Company.

 

It is noted that the Company is an SEC registrant (currently trading on the OTC with intent to be listed on the Canadian Stock Exchange) and that all quarterly and annual filings shall be prepared in accordance with SEC/exchange requirements, whereby Invictus and the Company shall work together to ensure all financial-related filings are completed within the deadlines of the applicable exchange(s)/regulators.

 

Personal Information

 

It is acknowledged that we may attain access to personal information in your custody that we may require to complete our Services. Our Services are provided on the basis that:

 

a)you represent to us that you have obtained any required consents for collection, use and disclosure to us of personal information required under applicable privacy legislation; and
   
 b)we will hold all personal information in compliance with applicable privacy legislation.

 

 

 

 Page 2 of 10 

 

 

File Inspections

 

In accordance with professional regulations (and by Firm policy), our client files must periodically be reviewed by practice inspectors and by other Firm personnel to ensure that we are adhering to professional and Firm standards. File reviewers are required to maintain confidentiality of client information.

 

Working Papers

 

The Deliverables including, but not limited to, the Company's financial statements, consolidation, equity workings, certifications, and other related project outputs and deliverables (including all historic accounting data and records of the Company that Invictus possesses), are the property of the Company and shall be returned/provided to the Company upon completion of the Services and receipt by Invictus of any outstanding balances owing for Services performed, as applicable. Pursuant to CPABC practice license (and insurance) requirements, copies of Deliverables and all documents related to the preparation of the Deliverables (including working papers, materials, correspondence, reports, files and work created, developed or performed by Invictus during the course of the engagement) constitute confidential information and may be retained by us in accordance with our standard terms and conditions and our Firm's policies and procedures. All proprietary methodology, systems, processes, and tools created by and/or utilized by Invictus, which were not expressly identified as Deliverables, remain the sole property of Invictus.

 

Governing Legislation

 

This engagement letter is subject to, and governed by, the laws of the Province of British Columbia and the laws of Canada applicable therein, without regard to principles of conflicts of law. The Province of British Columbia will have exclusive jurisdiction in relation to any claim, dispute or difference concerning this engagement letter and any matter arising from it. Each party irrevocably waives any right it may have to object to any action being brought in those courts to claim that the action has been brought in an inappropriate forum or to claim that those courts do not have jurisdiction.

 

Dispute Resolution
 

You agree that:

 

a)any dispute that may arise regarding the meaning, performance or enforcement of this engagement will, prior to resorting to litigation, be submitted to mediation; and

 

b)you will engage in the mediation process in good faith once a written request to mediate has been given by any party to the engagement.

 

Any mediation initiated as a result of this engagement shall be administered within the Province of British Columbia and any ensuing litigation shall be conducted within such province, according to provincial law. The results of any such mediation shall be binding only upon agreement of each party to be bound. The costs of any mediation proceeding shall be shared equally by the participating parties.

 

Costs of Responding to Government or Legal Processes

 

In the event we are required to respond to a subpoena, court order, government agency or other legal process for the production of documents and/or testimony relative to information we obtained and/or prepared during the course of this engagement, you agree to compensate us at our normal hourly rates for the time we expend in connection with such response and to reimburse us for all of our out-of-pocket costs (including applicable GST/HST) incurred.

 

 

 

 Page 3 of 10 

 

 

Communication

 

In connection with this engagement, we may communicate with you or others via telephone, facsimile, post, courier and e-mail transmission. As all communications can be intercepted or otherwise used or communicated by an unintended third party, or may not be delivered to each of the parties to whom they are directed and only to such parties, we cannot guarantee or warrant that communications from us will be properly delivered only to the addressee. Therefore, we specifically disclaim and waive any liability or responsibility whatsoever for interception or unintentional disclosure of communications transmitted by us in connection with the performance of this engagement. In that regard, you agree that we shall have no liability for any loss or damage to any person or entity resulting from: communications, including any consequential, incidental, direct or indirect; special damages, such as loss of revenues or anticipated profits; or disclosure or communication of confidential or proprietary information.

 

Non-solicitation and Non-inducement

 

The Company agrees not to solicit nor induce the employment of any employee or contractor of Invictus (the "Recruited Invictus Staff") without prior approval from Invictus. In the event the Company breaches this non-solicitation/non-inducement clause, the Company agrees to promptly pay Invictus a recruitment fee equal to 35% of the estimated first year annualized total compensation (salary and target bonus and/or consulting fee, as applicable) of the Recruited Invictus Staff. For certainty, this clause is not intended to be punitive nor impede employment opportunities, rather provide reasonable compensation to Invictus for potential re-staffing, recruitment, and training costs, as applicable.

 

Our Team

 

We are pleased to provide the services of Oliver Foeste, Managing Partner at Invictus, to provide CFO services (including named CFO, when applicable) and overall client service. Other staff may be assigned to the engagement as required to ensure the timelines required by the Company are met.

 

Our Guarantee

 

We guarantee our performance and people fit. If there are any problems with any staff we will adjust our staffing to meet your needs.

 

Timetable

 

Invictus shall begin work immediately, noting that the Services may begin gradually over a period of time, as advised by the CEO, and the named CFO role will transition to Oliver Foeste at a time the parties reasonably agree is acceptable for both of them.

 

Fees

 

Our fee estimate for the ongoing CFO, Financial Reporting, and Bookkeeping Services is $4,000 to $7,500 per month with the higher range expected during quarterly and annual financial reporting periods. This fee range will be refined during the first six months of the engagement as run-rates are determined. As applicable, additional fees may arise for the following:

 

·There may be a one-time "kick-off / clean-up" fee, while transitioning from a predecessor accounting firm / accountant, to address potential issues in historic workings, and potential improvements and/or catch-up work required to the Company's accounting systems and processes where deficiencies may exist.

 

·Special project fees may arise for merger and acquisition activities, or highly frequent / complicated financing transactions. We will advise and request approval (via email from a Company executive/director) for any special project fees prior to incurring the work.

 

 

 

 Page 4 of 10 

 

 

Our fees, subject to inflation, will be based on a time and materials basis, unless otherwise mutually agreed by the parties. Our hourly rate for the professionals performing the work (noting other titles may exist) will be in the ranges below, depending on the complexity of work conducted:

 

Partners, Principals and Specialists $225 to $400
Directors and Managers $135 to $225
Associates $ 90 to $135
Accounting Technicians / Bookkeepers $ 65 to $ 90

 

 

Fees are dependent upon access to information, complexity, and breadth of work required by the Company. If complexities arise, we will discuss with you prior to incurring any extra time.

 

We will bill for our services on a monthly basis. Payment is due upon invoice receipt. In the event other executive members of the Company are paid in the month of service, Invictus shall also then invoice and be paid in the month of service.

 

In addition to the fees outlined above, we shall bill for all reasonable expenses. Direct costs, including but not limited to travel, meals and accommodation will be charged as incurred. An administration fee of 2.5% of total fees will be charged to cover overhead expenses in connection with our engagement.

 

In addition to our fees, expenses and other charges payable pursuant to the engagement, we shall bill for all applicable taxes. We will not undertake additional work without your prior approval.

 

Stock-based Compensation and Other Executive Benefits

 

Stock Options

 

As part of the provision of CFO services, in the event that other executive team members have been granted stock options, the Company will promptly after the engagement letter date, grant a reasonable number of stock options to Invictus (and/or the named CFO, as directed by Invictus), with such number of stock options to be relative - considering the part time nature of the CFO role - to stock option grants provided to other Officers and Directors of the Company.

 

Change of Control

 

Notwithstanding Section 6 of the attached Standard Terms and Conditions, in the event that the CFO is terminated without cause at any time during the period from the date that is three months prior to any Change of Control to the date that is six months after any Change of Control, the CFO shall be entitled to a payment equal to three months of the CFO's fees (based on the average fees charged for the three months prior to such termination).

 

For the purpose of this section, a "Change of Control" means any of the following:

 

a)An acquisition by an arm's length third party of more than 50% of the voting securities of the Company; or

 

b)A sale of all or substantially all of the assets of the Company to an arm's length third party.

 

Directors and Officers ("D&O") Insurance

 

As a publicly listed entity the Company will always ensure to maintain sufficient D&O insurance/coverage. Retainer

 

Firm policy requires that we request a retainer up to 100% of the monthly fee estimate. We kindly request a retainer of $3,000.

 

 

 

 Page 5 of 10 

 

 

Standard Terms and Conditions

 

The Standard Terms and Conditions attached hereto are an integral part of this Agreement. This engagement letter should be read in conjunction with the Standard Terms and Conditions. In the event of conflict or inconsistency between the terms and conditions set forth in this engagement letter and the Standard Terms and Conditions, the terms and conditions set forth in this engagement letter shall take precedence.

 

Engagement Continuance and Amendments

 

The terms of this engagement letter supersede any prior oral or written representations or commitments by or between the parties and that this engagement letter includes the relevant terms that will govern the engagement for which it has been prepared.

 

Any material changes or additions to the terms set forth in this letter will only become effective if evidenced by a written amendment to this letter, signed by all of the parties.

 

We understand the above terms of our engagement shall remain in effect until amended.

 

 

 

 

 

 

 

 

 

 

 Page 6 of 10 

 

 

We are pleased to have the opportunity to provide our services to CannaPharmaRX Inc. and appreciate your confidence in us. If you have any questions, please call Oliver Foeste at 604-259-3112 or 604-230-3071. If the Services outlined herein are in accordance with your requirements and if the above terms are acceptable to you, please have one copy of this letter signed in the space provided below and return it to us.

 

 

Very truly yours,

 

/s/ Oliver Foeste                                

Oliver Foeste, CPA, CA

Invictus Accounting Group LLP

Chartered Professional Accountants

 

Confirmation of Terms of Engagement

 

Having read both the engagement letter and the Standard Terms and Conditions, we agree to engage Invictus Accounting Group LLP upon the terms set out therein.

 

CannaPharmaRX Inc.

 

By: /s/ Dean P. Medwid  
  (Signature)  

 

  Dean P. Medwid  
  (Print Name & Title)  
     
  July 25, 2023  
  (Date)  
     

 

 

 

 

 

 

 

 

 

 

 

Document — CannaPharmaRX Inc. — Engagement Letter CFO and Accounting Services - 2023

 Page 7 of 10 

 

 

  Standard Terms and Conditions

 

 

Except as otherwise specifically provided, these terms and conditions shall apply to any engagement carried out under this Agreement by Invictus Accounting Group LLP ("Invictus"). For the purposes of this Agreement, the term Invictus includes Invictus and its subcontractors and their respective partners, directors, officers and employees.

 

1.Timely Performance — Invictus will use all reasonable efforts to complete the performance of the Services within the time-frame stipulated. Invictus will exercise due professional care and competence in the performance of the Services. Invictus shall not be liable for failures or delays in the performance of Services that arise from causes beyond its control, including the untimely performance by the Company, its assigns, representatives, advisors or agents, of its obligations under this Agreement.

 

2.Company Responsibilities — The Company will provide to Invictus in a timely manner complete and accurate information and access to management personnel, staff, premises, computer systems and applications as is reasonably required by Invictus to complete the performance of the Services.

 

3.Confidentiality — In connection with the Services, Invictus will be given, or may obtain access to proprietary or confidential information of the Company and its affiliates, including information that, by the nature of its disclosure or its content, would reasonably be considered to be proprietary or confidential to the Company or its affiliates (collectively, "Confidential Information"). At all times during and after the term of the Services, Invictus will not disclose or use any Confidential Information, except in the course of carrying out authorized activities on behalf of the Company per this engagement letter or except as expressly authorized by the Company in writing. Invictus may, however, use or disclose Confidential Information that

 

i.is or becomes public, other than through a breach of this contract; or

 

ii.is required to be disclosed by law, whether under an order of a court or government tribunal or other legal process, provided that Invictus informs the Company of such requirement as soon as Invictus becomes aware of the requirement and in sufficient time to allow the Company to take such steps as are lawfully available to the Company to avoid or limit such disclosure.

 

4.Privacy — The Company confirms to Invictus that it has obtained any consent that may be required under applicable privacy legislation for the collection, use and disclosure to Invictus of personal information. Invictus shall adhere to applicable privacy legislation when dealing with personal information that was obtained from the Company.

 

5.Internet Communications — Unless otherwise agreed with the Company, Invictus may correspond by means of the Internet or other electronic media. Because of the inherent risks associated with the electronic transmission of information on the Internet or otherwise, Invictus does not guarantee the security and integrity of any electronic communications sent or received in relation to this engagement. Whilst it is Invictus' policy to check its email correspondence with anti-virus software, Invictus does not guarantee that transmissions will be free from infection and accepts no responsibility or liability for any damages as a result of communicating by means of the Internet or other electronic media.

 

6.Right to Terminate Services — Either party may terminate this Agreement, with or without cause, by providing 90 days written notice (the "CFO Notice Period") to the other party, noting that the CFO Notice Period may be shortened as mutually agreed, with the parties acting reasonably. In the event of early termination by the Company, for whatever reason, the Company will be invoiced for the greater of (i) time and expenses incurred up to the end of the CFO Notice Period together with reasonable time and expenses incurred to bring the engagement to a close in a prompt and orderly manner, or (ii) the average of the last six months of monthly fees for each month of the Notice Period (three months). Invictus shall also have the right, upon 7 days prior notice, to suspend performance of the Services in the event the Company fails to pay any amount required to be paid under this Agreement.

 

 

 

 Page 8 of 10 

 

 

  Standard Terms and Conditions

 

 

7.Billing — Bills including expenses will be rendered on a regular basis as the assignment progresses. Accounts are due when rendered. Interest on overdue accounts will commence 30 days following the date of the invoice at a rate of 2% per month.

 

8.Taxes — The fees, expenses and other charges payable pursuant to this Agreement do not include taxes or duties. All applicable taxes or duties, whether presently in force or imposed in the future, shall be assumed and paid by the Company without deduction from the fees, expenses and charges hereunder.

 

9.Governing Law — This Agreement shall be governed by and construed in accordance with the laws of the Province of British Columbia and the laws of Canada applicable therein, without regard to principles of conflicts of law. The parties hereby irrevocably and unconditionally attorn to the exclusive jurisdiction of the courts of the Province of British Columbia and all courts competent to hear appeals therefrom.

 

10.Templates/Working Papers/Reports — Subject to the restrictions in this engagement letter, the Company will own its financial statements, consolidation, equity workings, certifications, and other related project outputs and deliverables (including all historic accounting data and records of the Company that Invictus possesses) (the "Deliverables"). Invictus shall own all proprietary methodology, systems, processes, and tools created by and/or utilized by Invictus, which were not expressly identified as Deliverables, which may have been discovered, created, developed or derived by Invictus either prior to or as a result of its provision of Services under this Agreement. Invictus accepts no liability or responsibility to any Third Party who benefits from or uses the Services or gains access to the Deliverables.

 

11.Indemnification —The Company agrees to indemnify and hold Invictus harmless from and against any and all costs, charges, liabilities, damages, claims, demands, judgments and expenses (including solicitors' fees and disbursements) ("Costs") arising out of or based upon: (i) any intentional misstatement or omission in any material, information or representation supplied or approved by client; or (ii) any third party civil or administrative action or proceeding to which Invictus may be made a party and which is related to, arises out of, or is in any way associated with the engagement. The Company shall reimburse Invictus for the Costs as they are incurred. The indemnities described in this section shall not apply to any Costs resulting from the negligent, wrongful or willful acts or omissions of Invictus.

 

12.Limitation of Liability — In any action, claim, loss or damage (whether in tort, contract or otherwise) arising out of the engagement to which these terms and conditions are attached ("Claim") the parties agree that:

 

  i. Subject to the limits set out below in paragraphs (ii) and (iii), Invictus' liability shall be several and not joint and several, solidary or in solidum and Invictus shall only be liable for its proportionate share of the total liability based on degree of fault;
     
  ii. Under no circumstances shall Invictus be liable for damages in respect of any incidental, punitive, special, indirect or consequential loss, even if Invictus has been advised of the possibility of such damages including but not limited to loss of profits, loss of revenues, failure to realize expected savings, loss of data, loss of business opportunity, or similar losses of any kind; and
     
  iii. Invictus' total liability for any Claim arising out of the performance of the Services, regardless of the form of Claim, shall in no event exceed an amount equal to: (i) the total fees paid to Invictus under this Agreement; or (ii) the total fees paid to Invictus with respect to the Services directly relating to and forming the basis of such Claim, where the Claim arises from Services that are not subject to an agreement. This clause shall not limit Invictus' liability for death, personal injury or property damage caused by the negligent acts or omissions of Invictus and its partners and staff, or for loss or damage caused by their fraud or willful misconduct.

 

 

 

 Page 9 of 10 

 

 

  Standard Terms and Conditions

 

 

13.No Application — The preceding two sections (Indemnification, Limitation on Liability), or any portion of them, shall have no application to any liability for which exclusion or restriction is prohibited by law.

 

14.Severability — If any of the provisions of these terms and conditions are determined to be invalid or unenforceable, the remaining provisions shall remain in effect and be binding on the parties to the fullest extent permitted by law.

 

15.Proceeds of Crime (Money Laundering) and Terrorist Financing Act — Pursuant to this legislation, all accountants and securities dealers (including those providing portfolio management or investment counseling services) in Canada are required, in certain circumstances, to report any "suspicious transactions" to the Financial Transactions and Reports Analysis Centre of Canada (FINTRAC), a government agency. Suspicious transactions are transactions, which may relate to money laundering and the financing of terrorist activities.

 

16.Legal Proceedings — In the event Invictus is requested or authorized by the Company or is required by government regulation, subpoena, or other legal process to produce documents or personnel as witnesses with respect to the engagement for client, and provided that Invictus is not a party to the legal proceedings, the Company shall reimburse Invictus for professional time and expenses, as well as the fees and expenses of counsel, incurred in responding to such requests.

 

17.Promotion rights — Acting reasonably, Invictus may, in a limited and reputable fashion, selectively include the Company's name or logo as a "client" on select Invictus marketing materials and the Invictus website. For certainty, any potential disclosure of the Company's name/logo would exclude any mention of scope of work, fees, duration, or other.

 

18.Miscellaneous — Invictus shall provide all Services as an independent contractor and nothing shall be construed to create a partnership, joint venture or other relationship between Invictus and client. Neither party shall have the right, power or authority to obligate or bind the other in any manner. This Agreement shall not be modified except by written agreement between the parties. The Agreement represents the entire and sole agreement between the parties. Any terms and provisions of this Agreement that by their nature operate beyond the term or expiry of this Agreement shall survive the termination or expiry of this Agreement, including without limitation those provisions headed Confidentiality, Indemnification, Limitation on Liability, and Legal Proceedings.

 

 

 

 

 

 

 

 

 Page 10 of 10 

 

EX-101.SCH 3 cpmd-20231009.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cpmd-20231009_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cpmd-20231009_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 image01.jpg GRAPHIC begin 644 image01.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 09, 2023
Entity File Number 333-251016
Entity Registrant Name CannaPharmaRX, Inc.
Entity Central Index Key 0001081938
Entity Tax Identification Number 27-4635140
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Suite 3600
Entity Address, Address Line Two 888-3rd Street SW
Entity Address, City or Town Calgary
Entity Address, State or Province AB
Entity Address, Country CA
Entity Address, Postal Zip Code T2P 5C5
City Area Code (949)
Local Phone Number 652-6838
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CPMD
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 cannapharmarx_8k_htm.xml IDEA: XBRL DOCUMENT 0001081938 2023-10-09 2023-10-09 iso4217:USD shares iso4217:USD shares 0001081938 false 8-K 2023-10-09 CannaPharmaRX, Inc. DE 333-251016 27-4635140 Suite 3600 888-3rd Street SW Calgary AB CA T2P 5C5 (949) 652-6838 false false false false Common Stock, par value $0.0001 per share CPMD true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " 980 !X M;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " # =$U7)!Z;HJT #X 0 &@ M @ 'V$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " # =$U799!YDAD! #/ P $P @ ';$@ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" E% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cannapharmarx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cannapharmarx_8k.htm cpmd-20231009.xsd cpmd-20231009_lab.xml cpmd-20231009_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cannapharmarx_8k.htm": { "nsprefix": "CPMD", "nsuri": "http://cannapharmarx.com/20231009", "dts": { "inline": { "local": [ "cannapharmarx_8k.htm" ] }, "schema": { "local": [ "cpmd-20231009.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cpmd-20231009_lab.xml" ] }, "presentationLink": { "local": [ "cpmd-20231009_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://cannapharmarx.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cannapharmarx_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cannapharmarx_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://cannapharmarx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001683168-23-007145-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-23-007145-xbrl.zip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end